WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017185949) ANTIBODY TARGETED AGAINST CD20
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/185949    International Application No.:    PCT/CN2017/079303
Publication Date: 02.11.2017 International Filing Date: 01.04.2017
IPC:
C07K 16/28 (2006.01), C12N 15/13 (2006.01), C12N 15/85 (2006.01), C12N 5/10 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01)
Applicants: ZHAO, Lei [CN/CN]; (CN)
Inventors: ZHAO, Lei; (CN).
ZHANG, Fan; (CN)
Agent: LECOME INTELLECTUAL PROPERTY AGENT LTD.; Fl.16, Tower B, INDO Mansion, No.48-Jia Zhichun Road, Haidian District Beijing 100098 (CN)
Priority Data:
201610257652.2 24.04.2016 CN
Title (EN) ANTIBODY TARGETED AGAINST CD20
(FR) ANTICORPS DIRIGÉ CONTRE CD20
(ZH) 一种抗CD20靶向抗体
Abstract: front page image
(EN)A novel CD20 antibody and an application thereof in preparing anti-tumor drugs, and more specifically, a novel CD20 antibody having advantages of type I and II CD20 antibodies, a nucleic acid sequence and an amino acid sequence thereof, and an application thereof in preparing anti-tumor drugs. This antibody not only reserves the function of type I CD20 antibody of inducing strong CDC killing, but also has the advantage of type II CD20 antibody of inducing strong cell death, and thus has an anti-tumor activity better than those of the parental type I CD20 antibody Rituximab and type II CD20 antibody, thereby having great potential applications.
(FR)L'invention concerne un nouvel anticorps anti-CD20 et une application de celui-ci dans la préparation de médicaments anti-tumoraux, et plus spécifiquement, un nouvel anticorps anti-CD20 ayant les avantages d'anticorps anti-CD20 de type I et II, une séquence d'acide nucléique et une séquence d'acides aminés de celui-ci, ainsi qu'une application de celui-ci dans la préparation de médicaments anti-tumoraux. Cet anticorps non seulement conserve la fonction de l'anticorps anti-CD20 de type I d'induction d'une forte destruction des CDC, mais aussi possède l'avantage d'un anticorps anti-CD20 de type II d'induction d'une mort cellulaire forte, et présente donc une activité antitumorale meilleure que celles de l'anticorps anti-CD20 de type I parent Rituximab et de l'anticorps anti-CD20 de type II, permettant ainsi de vastes applications potentielles.
(ZH)一类新型CD20抗体及其在制备抗体肿瘤药物中的应用,更具体地,兼具I型和II型CD20抗体优势的新型CD20抗体,其核酸序列、氨基酸序列及其在制备抗肿瘤药物中的应用,该抗体既保留了I型CD20抗体诱导强烈CDC杀伤的功能,又兼具II型CD20抗体的优势,能够诱导强烈的细胞死亡,具有比亲本I型CD20抗体Rituximab和II型CD20抗体更好的抗肿瘤活性,具有巨大的应用前景。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)